Botulinum Neurotoxin Treatment of Cranial-Cervical Dystonia

Botulinum Toxin: Therapeutic Clinical Practice and Science

Volumn , Issue , 2009, Pages 92-101

  Kenney, Christopher ^a   Jankovic, Joseph ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 72849106160     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-4928-9.00008-1     Document Type: Chapter

References (102)

1. Shahed J, Jankovic J Handbook of Dystonia 2007, Taylor & Francis Group, New York, In press. M. Stacy (Ed.).
2. Hallett M Pathophysiology of dystonia. J Neural Transm Suppl 2006, 70:485-488.
3. Sitburana O, Jankovic J Focal hand dystonia, mirror dystonia and motor overflow. J Neurol Sci 2007, In press.
4. Ben Simon GJ, McCann JD Benign essential blepharospasm. Int Ophthalmol Clin 2005, 45:49-75.
5. Whitney CM Benign essential blepharospasm. Neurologist 2005, 11:193-194.
6. Cossu G, Mereu A, Deriu M, Melis M, Molari A, Melis G, et al. Prevalence of primary blepharospasm in Sardinia, Italy: A service-based survey. Mov Disord 2006, 21:2005-2008.
7. Nutt JG, Muenter MD, Aronson A, Kurland LT, Melton LJ Epidemiology of focal and generalized dystonia in Rochester, Minnesota. Mov Disord 1988, 3:188-194.
8. Grandas F, Elston J, Quinn N, Marsden CD Blepharospasm: a review of 264 patients. J Neurol Neurosurg Psychiatry 1988, 51:767-772.
9. Reimer J, Gilg K, Karow A, Esser J, Franke GH Health-related quality of life in blepharospasm or hemifacial spasm. Acta Neurol Scand 2005, 111:64-70.
10. Jankovic J, Orman J Blepharospasm: demographic and clinical survey of 250 patients. Ann Ophthalmol 1984, 16:371-376.
11. Mejia NI, Jankovic J Secondary tics and tourettism. Rev Bras Psiquiatr 2005, 27:11-17.
12. Jankovic J Apraxia of lid opening. Mov Disord 1995, 10:686-687.
13. Cardoso F, de Oliveira JT, Puccioni-Sohler M, Fernandes AR, de, Mattos JP, Lopes-Cendes I Eyelid dystonia in Machado-Joseph disease. Mov Disord 2000, 15:1028-1030.
14. Kerty E, Eidal K Apraxia of eyelid opening: clinical features and therapy. Eur J Ophthalmol 2006, 16:204-208.
15. Wessberg G Management of oromandibular dystonia. Hawaii Dent J 2003, 34:15-16.
16. Brin MF, Benabou R Cervical dystonia (torticollis). Curr Treat Options Neurol 1999, 1:33-43.
17. Claypool DW, Duane DD, Ilstrup DM, Melton LJ Epidemiology and outcome of cervical dystonia (spasmodic torticollis) in Rochester, Minnesota. Mov Disord 1995, 10:608-614.
18. Jankovic J Botulinum toxin therapy for cervical dystonia. Neurotox Res 2006, 9:145-148.
19. Pal PK, Samii A, Schulzer M, Mak E, Tsui JK Head tremor in cervical dystonia. Can J Neurol Sci 2000, 27:137-142.
20. Kutvonen O, Dastidar P, Nurmikko T Pain in spasmodic torticollis. Pain 1997, 69:279-286.
21. Soland VL, Bhatia KP, Marsden CD Sex prevalence of focal dystonias. J Neurol Neurosurg Psychiatry 1996, 60:204-205.
22. van Harten PN, Kahn RS Tardive dystonia. Schizophr Bull 1999, 25:741-748.
23. Jankovic J Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov Disord 2005, 20(Suppl 11):S11-S16.
24. Lynch T, Fahn S, Louis ED, Odel JG Oculofacial-skeletal myorhythmia in Whipple's disease. Mov Disord 1997, 12:625-626.
25. Jankovic J Can peripheral trauma induce dystonia and other movement disorders? Yes!. Mov Disord 2001, 16:7-12.
26. Ljubisavljevic M, Kacar A, Milanovic S, Svetel M, Kostic VS Changes in cortical inhibition during task-specific contractions in primary writing tremor patients. Mov Disord 2006, 21:855-859.
27. van Eimeren T, Siebner HR An update on functional neuroimaging of parkinsonism and dystonia. Curr Opin Neurol 2006, 19:412-419.
28. Naumann M, Reiners K Long-latency reflexes of hand muscles in idiopathic focal dystonia and their modification by botulinum toxin. Brain 1997, 120(Pt 3):409-416.
29. Dresel C, Haslinger B, Castrop F, Wohlschlaeger AM, Ceballos-Baumann AO Silent event-related fMRI reveals deficient motor and enhanced somatosensory activation in orofacial dystonia. Brain 2006, 129:36-46.
30. Schneider SA, Mohire MD, Trender-Gerhard I, Asmus F, Sweeney M, Davis M, et al. Familial dopa-responsive cervical dystonia. Neurology 2006, 66:599-601.
31. Nasir J, Frima N, Pickard B, Malloy MP, Zhan L, Grunewald R Unbalanced whole arm translocation resulting in loss of 18p in dystonia. Mov Disord 2006, 21:859-863.
32. Jankovic J Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry 2004, 75:951-957.
33. Jankovic J Treatment of dystonia. Lancet Neurol 2006, 5:864-872.
34. Berardelli A, Curra A Pathophysiology and treatment of cranial dystonia. Mov Disord 2002, 17(suppl 2):S70-S74.
35. Greene P Baclofen in the treatment of dystonia. Clin Neuropharmacol 1992, 15:276-288.
36. Lang AE, Riley DE Tizanidine in cranial dystonia. Clin Neuropharmacol 1992, 15:142-147.
37. Kenney C, Jankovic J Tetrabenazine in the treatment of hyperkinetic movement disorders. Expert Rev Neurother 2006, 6:7-17.
38. Kenney C, Hunter C, Jankovic J Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord 2007, 22:193-197.
39. Scott AB, Kennedy RA, Stubbs HA Botulinum A toxin injection as a treatment for blepharospasm. Arch Ophthalmol 1985, 103:347-350.
40. Truong DD, Jost WH Botulinum toxin: clinical use. Parkinsonism Relat Disord 2006, 12:331-355.
41. Naumann M, Albanese A, Heinen F, Molenaers G, Relja M Safety and efficacy of botulinum toxin type A following long-term use. Eur J Neurol 2006, 13(suppl 4):35-40.
42. Mejia NI, Vuong KD, Jankovic J Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov Disord 2005, 20:592-597.
43. Vidailhet M, Vercueil L, Houeto JL, Krystkowiak P, Lagrange C, Yelnik J, et al. Bilateral, pallidal, deep-brain stimulation in primary generalised dystonia: a prospective 3 year follow-up study. Lancet Neurol 2007, 6:223-229.
44. Hung SW, Hamani C, Lozano AM, Poon YY, Piboolnurak P, Miyasaki JM, et al. Long-term outcome of bilateral pallidal deep brain stimulation for primary cervical dystonia. Neurology 2007, 68:457-459.
45. Houser M, Waltz T Meige syndrome and pallidal deep brain stimulation. Mov Disord 2005, 20:1203-1235.
46. Ostrem JL, Marks WJ, Volz MM, Heath SL, Starr PA Pallidal deep brain stimulation in patients with cranial-cervical dystonia (Meige syndrome). Mov Disord 2007, 22:1885-1891.
47. Kupsch A, Benecke R, Muller J, Trottenberg T, Schneider GH, Poewe W, et al. Pallidal deep-brain stimulation in primary generalized or segmental dystonia. N Engl J Med 2006, 355:1978-1990.
48. Kenney C, Simpson R, Hunter C, Ondo W, Almaguer M, Davidson A, et al. Short-term and long-term safety of deep brain stimulation in the treatment of movement disorders. J Neurosurg 2007, 106:621-625.
49. Kenney C, Jankovic J Botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J Neural Transm 2007, 115:585-591.
50. Costa J, Espirito-Santo C, Borges A, Ferreira JJ, Coelho M, Moore P, et al. Botulinum toxin type A therapy for blepharospasm. Cochrane Database Syst Rev. 2005;CD004900.
51. Fahn S, List T, Moslowitz C, Brin M, Bressman SB, Burke RE, et al. Double-blind controlled study of botulinum toxin for blepharospasm. Neurology 1985, 35(suppl 1):271-272.
52. Jankovic J, Orman J Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology 1987, 37:616-623.
53. Roggenkamper P, Jost WH, Bihari K, Comes G, Grafe S Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm 2006, 113:303-312.
54. Iwashige H, Nemeto Y, Takahashi H, Maruo T Botulinum toxin type A purified neurotoxin complex for the treatment of blepharospasm: a dose-response study measuring eyelid force. Jpn J Ophthalmol 1995, 39:424-431.
55. Frueh BR, Nelson CC, Kapustiak JF, Musch DC The effect of omitting botulinum toxin from the lower eyelid in blepharospasm treatment. Am J Ophthalmol 1988, 106:45-47.
56. Park YC, Lim JK, Lee DK, Yi SD Botulinum a toxin treatment of hemifacial spasm and blepharospasm. J Korean Med Sci 1993, 8:334-340.
57. MacAndie K, Kemp E Impact on quality of life of botulinum toxin treatments for essential blepharospasm. Orbit 2004, 23:207-210.
58. Tucha O, Naumann M, Berg D, Alders GL, Lange KW Quality of life in patients with blepharospasm. Acta Neurol Scand 2001, 103:49-52.
59. Sampaio C, Ferreira JJ, Simoes F, Rosas MJ, Magalhaes M, Correia AP, et al. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A-Dysport and Botox-assuming a ratio of 4:1. Mov Disord 1997, 12:1013-1018.
60. Rieder CR, Schestatsky P, Socal MP, Monte TL, Fricke D, Costa J, et al. A double-blind, randomized, crossover study of prosigne versus botox in patients with blepharospasm and hemifacial spasm. Clin Neuropharmacol 2007, 30:39-42.
61. Levy RL, Berman D, Parikh M, Miller NR Supramaximal doses of botulinum toxin for refractory blepharospasm. Ophthalmology 2006, 113:1665-1668.
62. Pang AL, O'Day J Use of high-dose botulinum A toxin in benign essential blepharospasm: is too high too much?. Clin Experiment Ophthalmol 2006, 34:441-444.
63. Cakmur R, Ozturk V, Uzunel F, Donmez B, Idiman F Comparison of preseptal and pretarsal injections of botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J Neurol 2002, 249:64-68.
64. Albanese A, Bentivoglio AR, Colosimo C, Galardi G, Maderna L, Tonali P Pretarsal injections of botulinum toxin improve blepharospasm in previously unresponsive patients. J Neurol Neurosurg Psychiatry 1996, 60:693-694.
65. Jankovic J Pretarsal injection of botulinum toxin for blepharospasm and apraxia of eyelid opening. J Neurol Neurosurg Psychiatry 1996, 60:704.
66. Kowal L Pretarsal injections of botulinum toxin improve blepharospasm in previously unresponsive patients. J Neurol Neurosurg Psychiatry 1997, 63:556.
67. Mauriello JA, Keswani R, Franklin M Long-term enhancement of botulinum toxin injections by upper-eyelid surgery in 14 patients with facial dyskinesias. Arch Otolaryngol Head Neck Surg 1999, 125:627-631.
68. Jankovic J, Vuong KD, Ahsan J Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 2003, 60:1186-1188.
69. Dutton JJ, White JJ, Richard MJ Myobloc for the treatment of benign essential blepharospasm in patients refractory to Botox. Ophthal Plast Reconstr Surg 2006, 22:173-177.
70. Chawda SJ, Munchau A, Johnson D, Bhatia K, Quinn NP, Stevens J, et al. Pattern of premature degenerative changes of the cervical spine in patients with spasmodic torticollis and the impact on the outcome of selective peripheral denervation. J Neurol Neurosurg Psychiatry 2000, 68:465-471.
71. Zesiewicz TA, Stamey W, Sullivan KL, Hauser RA Botulinum toxin A for the treatment of cervical dystonia. Expert Opin Pharmacother 2004, 5:2017-2024.
72. Gelb DJ, Yoshimura DM, Olney RK, Lowenstein DH, Aminoff MJ Change in pattern of muscle activity following botulinum toxin injections for torticollis. Ann Neurol 1991, 29:370-376.
73. Erdal J, Ostergaard L, Fuglsang-Frederiksen A, Werdelin L, Dalager T, Sjo O, et al. Long-term botulinum toxin treatment of cervical dystonia-EMG changes in injected and noninjected muscles. Clin Neurophysiol 1999, 110:1650-1654.
74. Buchman AS, Comella CL, Stebbins GT, Tanner CM, Goetz CG Quantitative electromyographic analysis of changes in muscle activity following botulinum toxin therapy for cervical dystonia. Clin Neuropharmacol 1993, 16:205-210.
75. Dressler D, Rothwell JC Electromyographic quantification of the paralysing effect of botulinum toxin in the sternocleidomastoid muscle. Eur Neurol 2000, 43:13-16.
76. Ostergaard L, Fuglsang-Frederiksen A, Sjo O, Werdelin L, Winkel H Quantitative EMG in cervical dystonia. Electromyogr Clin Neurophysiol 1996, 36:179-185.
77. Brans JW, Aramideh M, Koelman JH, Lindeboom R, Speelman JD, Ongerboer de Visser BW Electromyography in cervical dystonia: changes after botulinum and trihexyphenidyl. Neurology 1998, 51:815-819.
78. Van Gerpen JA, Matsumoto JY, Ahlskog JE, Maraganore DM, McManis PG Utility of an EMG mapping study in treating cervical dystonia. Muscle Nerve 2000, 23:1752-1756.
79. Comella CL, Buchman AS, Tanner CM, Brown-Toms NC, Goetz CG Botulinum toxin injection for spasmodic torticollis: increased magnitude of benefit with electromyographic assistance. Neurology 1992, 42:878-882.
80. Comella CL, Jankovic J, Brin MF Use of botulinum toxin type A in the treatment of cervical dystonia. Neurology 2000, 55:S15-S21.
81. Jankovic J Treatment of cervical dystonia with botulinum toxin. Mov Disord 2004, 19(Suppl 8):S109-S115.
82. Factor SA, Molho ES, Evans S, Feustel PJ Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia. Mov Disord 2005, 20:1152-1160.
83. Truong D, Duane DD, Jankovic J, Singer C, Seeberger LC, Comella CL, et al. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord 2005, 20:783-791.
84. Ceballos-Baumann AO Evidence-based medicine in botulinum toxin therapy for cervical dystonia. J Neurol 2001, 248(suppl 1):14-20.
85. Jankovic J, Esquenazi A, Fehlings D, Freitag F, Lang AM, Naumann M Evidence-based review of patient-reported outcomes with botulinum toxin type A. Clin Neuropharmacol 2004, 27:234-244.
86. Greene P, Kang U, Fahn S, Brin M, Moskowitz C, Flaster E Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology 1990, 40:1213-1218.
87. Kessler KR, Skutta M, Benecke R Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group 1999, 246:265-274.
88. Lew MF, Brashear A, Factor S The safety and efficacy of botulinum toxin type B in the treatment of patients with cervical dystonia: summary of three controlled clinical trials. Neurology 2000, 55:S29-S35.
89. Brashear A, Lew MF, Dykstra DD, Comella CL, Factor SA, Rodnitzky RL, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 1999, 53:1439-1446.
90. Brin MF, Lew MF, Adler CH, Comella CL, Factor SA, Jankovic J, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 1999, 53:1431-1438.
91. Lew MF, Adornato BT, Duane DD, Dykstra DD, Factor SA, Massey JM, et al. Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology 1997, 49:701-707.
92. Anderson TJ, Rivest J, Stell R, Steiger MJ, Cohen H, Thompson PD, et al. Botulinum toxin treatment of spasmodic torticollis. J R Soc Med 1992, 85:524-529.
93. Borodic GE, Pearce LB, Smith K, Joseph M Botulinum a toxin for spasmodic torticollis: multiple vs single injection points per muscle. Head Neck 1992, 14:33-37.
94. Brans JW, Lindeboom R, Snoek JW, Zwarts MJ, van Weerden TW, Brunt ER, et al. Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial. Neurology 1996, 46:1066-1072.
95. Poewe W, Deuschl G, Nebe A, Feifel E, Wissel J, Benecke R, et al. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group 1998, 64:13-17.
96. Laubis-Herrmann U, Fries K, Topka H Low-dose botulinum toxin-a treatment of cervical dystonia-a double-blind, randomized pilot study. Eur Neurol 2002, 47:214-221.
97. Skogseid IM, Kerty E The course of cervical dystonia and patient satisfaction with long-term botulinum toxin A treatment. Eur J Neurol 2005, 12:163-170.
98. Tarsy D Comparison of acute- and delayed-onset posttraumatic cervical dystonia. Mov Disord 1998, 13:481-485.
99. Jankovic J, Schwartz KS Use of botulinum toxin in the treatment of hand dystonia. J Hand Surg [Am] 1993, 18:883-1887.
100. Jankovic J, Hunter C, Dolimbek BZ, Dolimbek GS, Adler CH, Brashear A, et al. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology 2006, 67:2233-2235.
101. Jankovic J Botulinum toxin: Clinical implications of antigenicity and immunoresistance. Scientific and Therapeutic Aspects of Botulinum Toxin 2002, 409-416. Lippincott Williams & Wilkins, Philadelphia. M.F. Brin, M. Hallett, J. Jankovic (Eds.).
102. Cordivari C, Misra VP, Vincent A, Catania S, Bhatia KP, Lees AJ Secondary nonresponsiveness to botulinum toxin A in cervical dystonia: the role of electromyogram-guided injections, botulinum toxin A antibody assay, and the extensor digitorum brevis test. Mov Disord 2006, 21:1737-1741.